The lancet oncology
-
The lancet oncology · Dec 2011
Randomized Controlled Trial Multicenter Study Comparative StudyAutologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Autologous haemopoietic stem-cell transplantation (HSCT) improves survival in patients with multiple myeloma, but disease progression remains an issue. Allogeneic HSCT might reduce disease progression, but can be associated with high treatment-related mortality. Thus, we aimed to assess effectiveness of allogeneic HSCT with non-myeloablative conditioning after autologous HSCT compared with tandem autologous HSCT. ⋯ US National Heart, Lung, and Blood Institute and the National Cancer Institute.
-
The lancet oncology · Dec 2011
Review Meta AnalysisPsychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis.
Ethnic minority is associated with higher cancer incidence and poorer survival than is being in the majority group. We did a systematic review and meta-analysis to assess whether psychological morbidity and health-related quality of life (HRQoL) were affected by minority status. ⋯ Prince of Wales Hospital, Sydney, Australia.
-
The lancet oncology · Dec 2011
Randomized Controlled Trial Multicenter Study Comparative StudyFludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Chronic lymphocytic leukaemia (CLL) is an incurable and chronic disorder, with worsening prognosis for patients as their disease progresses. We compared the efficacy and safety of the combination of fludarabine and alemtuzumab with fludarabine monotherapy in previously treated patients with relapsed or refractory CLL. ⋯ Genzyme.